Table 1 Baseline characteristics
From: Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
N (%) | ||
|---|---|---|
Age years | 72 (51–86) | |
Gender | F14 (32) M29 (68) | |
Follow-up months | 8 (1–37) | |
STAGE | Rai I/II | 23 (53) |
Rai III/IV | 20 (47) | |
Binet A/B | 26 (60) | |
Binet C | 17 (40) | |
FISH | del13 | 13 (30) |
trisomy 12 | 3 (7) | |
del17p or TP53 mut | 12 (28) | |
del11q | 5 (12) | |
VHIG | Mutated | 10/36 (28) |
Unmutated | 26/36 (72) | |
Treatment | First-line | 12 (28) |
≥Second line | 31 (72) | |
Cardiovascular comorbidities | Previous AF | 5 (12) |
AH | 23 (53) | |
Valvular heart disease | 20 (47) | |
CAD | 8 (19) | |
PAD | 4 (9) | |
Diabetes | 4 (9) | |
Hypothyroidism | 5 (12) | |
Dislipidaemia | 12 (28) | |
Smoke | 1 (2) | |
BMI > 25 | 7 (16) |